Adaptive Biotechnologies (ADPT) Total Debt (2022 - 2026)

Adaptive Biotechnologies has reported Total Debt for 5 years, with the latest figure at $130.6 million in Q1 2026.

• Quarterly Total Debt fell 2.25% year-over-year to $130.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.6 million (down 2.25% YoY) and the FY2025 annual result came in at $131.2 million, down 1.55% from the prior year.
• Total Debt held at $130.6 million in Q1 2026 per ADPT's latest filing, from $131.2 million in the prior quarter.
• Over five years, Total Debt peaked at $133.6 million in Q2 2025 and troughed at $125.4 million in Q4 2022.
• A 5-year average of $131.4 million and a median of $131.7 million in 2024 frame the typical range for Total Debt.
• The sharpest annual moves came in 2023 and 2026: Total Debt rose 4.23% in 2023, then fell 2.25% in 2026.
• Over 5 years, Total Debt stood at $125.4 million in 2022, then increased by 4.23% to $130.7 million in 2023, then gained by 2.0% to $133.3 million in 2024, then dropped by 1.55% to $131.2 million in 2025, then decreased by 0.5% to $130.6 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $130.6 million, $131.2 million, and $131.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.